

Contents lists available at [ScienceDirect](#)

Pharmacological Research

journal homepage: www.elsevier.com/locate/yphrs

Corrigendum to “Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update” [Pharmacol. Res. 200 (2024) 107059]

Robert Roskoski

Blue Ridge Institute for Medical Research, 221 Haywood Knolls Drive, Hendersonville, NC 28791, United States

In the abstract, the disease targeted by capivasertib is HR-positive, HER2-negative breast cancer. In Table 2, the target of capivasertib is AKT and the therapeutic indication is HR-positive, HER2-negative

breast cancer with genetic alterations of *PIK3CA/AKT1/PTEN*. The author apologises for any inconvenience caused to the readers.

DOI of original article: <https://doi.org/10.1016/j.phrs.2024.107059>.

E-mail address: rrj@brimr.org.

<https://doi.org/10.1016/j.phrs.2025.107804>

1043-6618/© 2025 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Please cite this article as: Robert Roskoski, *Pharmacological Research*, <https://doi.org/10.1016/j.phrs.2025.107804>